Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

• Teva outlines acceleration path into a leading biopharma company
• Innovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO (deutetrabenazine), AJOVY (fremanezumab), UZEDY (risperidone) and late-stage pipeline with blockbuster potential
• Reaffirming 2027 financial targets, including 30% operating profit margin, driven by innovative growth and transformation programs
  

TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation & Strategy Day, to launch the acceleration phase of its “Pivot to Growth” strategy and to discuss portfolio priorities as it evolves into a global biopharmaceutical leader. The event, led by President and CEO Richard Francis and members of Teva’s executive management team, will outline the company’s strategy, progress and roadmap to deliver sustained shareholder value through 2030 and beyond.

Presentations begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time. A live webcast of the event and presentation materials will be available on Teva's Investor Relations website at: https://ir.tevapharm.com/Events-and-Presentations.

Where We Are Today
Teva has completed Phase 1 of the Strategy: Return to Growth, delivering:

• 9 consecutive quarters of growth – fueled by strong momentum from key innovative growth drivers.
• More than $2.3 billion in revenue in 2024 from Teva’s innovative portfolio: AUSTEDO, AJOVY, and UZEDY.
• Returning the generics business to growth with +5% in revenues across regions, and top 3 global portfolio with potential for five product launches by 2027.
  

“The past two years have been about returning to growth and building a solid foundation. Today, Teva is a fundamentally different company – more focused, more innovative, and more robust. I am proud that we have delivered on our commitments,” said Richard Francis, Teva’s President and CEO. “Now, we are accelerating our growth into a leading biopharma company with a strong innovative medicines franchise and a powerhouse generics and biosimilars portfolio.”

Delivering on Our Growth Engines
Teva’s innovative portfolio continues to drive strong performance and future potential. The company has announced its target to build a >$5 billion innovative medicines franchise by 2030, driven by AUSTEDO, AJOVY, UZEDY, and a robust pipeline of late-stage assets including olanzapine LAI, duvakitug, DARI, and emrusolmin.